Ernexa Therapeutics Inc. (ERNA) stock
ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
$1.63−0.06 (-3.55%)
Close on Nov 17, 2026Market cap $2.66MP/E –Yield –
Ernexa Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Ernexa Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.84M. For fiscal 2025 it was -$7.02M. The highest annual figure on record is $2.83M in fiscal 2010.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.02M | – |
| FY2024 | Dec 31, 2024 | -$15.84M | – |
| FY2023 | Dec 31, 2023 | -$20.41M | – |
| FY2022 | Dec 31, 2022 | -$20.98M | – |
| FY2021 | Dec 31, 2021 | -$23.49M | – |
| FY2020 | Dec 31, 2020 | -$8.10M | -395.2% |
| FY2019 | Dec 31, 2019 | $2.74M | +101.0% |
| FY2018 | Dec 31, 2018 | $1.37M | +148.6% |
| FY2017 | Dec 31, 2017 | $549.00K | +2287.0% |
| FY2016 | Dec 31, 2016 | $23.00K | – |
| FY2015 | Dec 31, 2015 | -$4.18M | – |
| FY2014 | Dec 31, 2014 | -$6.39M | -466.7% |
| FY2013 | Dec 31, 2013 | $1.74M | -19.2% |
| FY2012 | Dec 31, 2012 | $2.16M | +275.6% |
| FY2011 | Dec 31, 2011 | $574.00K | -79.7% |
| FY2010 | Dec 31, 2010 | $2.83M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.15M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.27M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.07M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.66M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.87M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.99M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.43M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.83M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.42M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.80M | – |
| Q1 FY2021 | Mar 31, 2021 | -$3.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.64M | -266.6% |
| Q3 FY2020 | Sep 30, 2020 | -$2.41M | -670.3% |
| Q2 FY2020 | Jun 30, 2020 | -$2.18M | -490.6% |
| Q1 FY2020 | Mar 31, 2020 | -$1.87M | -340.1% |
| Q4 FY2019 | Dec 31, 2019 | $983.00K | +17.4% |
| Q3 FY2019 | Sep 30, 2019 | $422.00K | +46.0% |
| Q2 FY2019 | Jun 30, 2019 | $559.00K | +55.7% |
| Q1 FY2019 | Mar 31, 2019 | $780.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $837.00K | – |
| Q3 FY2018 | Sep 30, 2018 | $289.00K | – |
| Q2 FY2018 | Jun 30, 2018 | $359.00K | -89.0% |
| Q1 FY2018 | Mar 31, 2018 | -$120.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$507.00K | -1094.1% |
| Q3 FY2017 | Sep 30, 2017 | -$1.75M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.27M | – |
| Q1 FY2017 | Mar 31, 2017 | -$466.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $51.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$41.00K | – |
See a number that looks wrong?